Sponsor
|
Studies ↑
|
Description
|
Ready to Share
|
Created
|
|
ASTELLAS-0113-CL-2001
|
A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ from a CMV-Seropositive Donor
|
6/27/2022
|
|
ASTELLAS-015K-CL-CNA3
|
A Randomized, Double-Blind, Placebo-Controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to MTX
|
5/1/2024
|
|
ASTELLAS-015K-CL-PS01
|
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Multiple-Dose Escalation Study to Evaluate the Efficacy and Safety of ASP015K in Subjects with Moderate to Severe Plaque Psoriasis
|
3/31/2020
|
|
ASTELLAS-015K-CL-RA25
|
A Phase 2 Open-label, Noncomparative, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study
|
2/18/2020
|
|
ASTELLAS-015K-CL-RAJ1
|
Phase 2b Study of ASP015K – A Double-Blind, Placebo-Controlled, Dose-Finding Study in Moderate to Severe Rheumatoid Arthritis Patients –
|
7/14/2020
|
|
ASTELLAS-015K-CL-RAJ2
|
Open-label Extension Study in Rheumatoid Arthritis Patients Who Have Completed Phase 2b Study or Phase 3 Study of ASP015K
|
7/13/2021
|
|
ASTELLAS-015K-CL-RAJ3
|
Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to DMARDs -
|
7/14/2020
|
|
ASTELLAS-015K-CL-RAJ4
|
Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to MTX -
|
7/14/2020
|
|
ASTELLAS-0456-CL-1021
|
Phase II Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study in Patients With Chronic Constipation (Not Including Constipation Due to Organic Diseases)
|
2/28/2020
|
|
ASTELLAS-0456-CL-1031
|
Phase 3 Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study and an Open-label, Uncontrolled, Long-term Dosing Study in Patients with Chronic Constipation (Not Including Constipation Due to Organic Diseases) -
|
2/28/2020
|